STOCK TITAN

aiki - $aiki STOCK NEWS

Welcome to our dedicated page for aiki news (Ticker: $aiki), a resource for investors and traders seeking the latest updates and insights on aiki stock.

AIkido Pharma Inc., established in 1967, is a biotechnology company focusing on developing small-molecule anti-cancer therapeutics. The company leverages patented technology from leading universities and esteemed researchers to create an innovative drug platform. AIkido Pharma has forged significant partnerships with renowned institutions such as The University of Texas at Austin and Wake Forest University. The company's diverse pipeline includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Besides oncology, AIkido Pharma is expanding its portfolio to address unmet medical needs, including developing a broad-spectrum antiviral platform targeting viruses like Influenza, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus.

In recent news, AIkido Pharma has been active with its $2 million share repurchase program, showcasing commitment to shareholder value. The company also highlights its collaborations and achievements in the broader biotechnology landscape, aiming to bring groundbreaking treatments to market. Investors and stakeholders can follow the latest updates and developments as AIkido Pharma continues to enhance its therapeutic offerings and strengthen its market presence.

Rhea-AI Summary
DatChat, Inc. (Nasdaq: DATS) announces 1-for-10 reverse stock split to meet Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DATCHAT announces a 1:10 reverse stock split to comply with Nasdaq's minimum bid price requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
DatChat to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
conferences
Rhea-AI Summary
DatChat files patent application for Secure Group Based Asset Access and surpasses 100,000 members in its metaverse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.41%
Tags
none
-
Rhea-AI Summary
DatChat partners with Cloud Water Brands to promote their products within the Habytat Virtual World.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
partnership
-
Rhea-AI Summary
DatChat reaches milestone of over 75,000 active users in Habytat metaverse, with accelerated adoption of AI-powered HabyPets. Company confident in converting user growth into revenue streams. Expectation of higher user growth with new product releases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
AI
Rhea-AI Summary
DatChat launches AI-powered pets called HabyPets in its Habytat metaverse, with initial breeds including Shiba Inu, German Shepherd, Golden Retriever, and Schnauzer. Pets require daily care and training. Revenue growth expected from advertisements and product placements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
Rhea-AI Summary
DATS: DatChat Receives USPTO Allowance for Secure Web RTC Real Time Communication Service Patent. The patent enhances security for audio and video streaming communications, further solidifying DatChat's commitment to protecting user information and expanding capabilities in the metaverse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
conferences

FAQ

What is AIkido Pharma Inc.'s primary focus?

AIkido Pharma Inc. focuses on developing small-molecule anti-cancer therapeutics and broad-spectrum antiviral platforms.

What recent achievements has AIkido Pharma Inc. accomplished?

AIkido Pharma Inc. has advanced its therapeutic drug platform and initiated a $2 million share repurchase program.

Who are AIkido Pharma Inc.'s key partners?

The company has significant partnerships with The University of Texas at Austin and Wake Forest University.

What types of cancer therapies does AIkido Pharma Inc. develop?

AIkido Pharma Inc. develops therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

Is AIkido Pharma Inc. involved in antiviral research?

Yes, AIkido Pharma Inc. is developing a broad-spectrum antiviral platform targeting viruses such as Influenza, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus.

How does AIkido Pharma Inc. contribute to oncology research?

AIkido Pharma Inc. contributes by developing innovative small-molecule therapies and continually expanding its pipeline to address unmet medical needs in oncology.

What is the company's approach to enhancing shareholder value?

AIkido Pharma Inc. has initiated a $2 million share repurchase program as part of its efforts to enhance shareholder value.

How does AIkido Pharma Inc. utilize its partnerships?

The company leverages its partnerships to access cutting-edge research and technology from leading universities and researchers, enhancing its drug development platform.

What makes AIkido Pharma Inc.'s antiviral platform unique?

AIkido Pharma Inc.'s antiviral platform is designed to inhibit replication of multiple viruses, offering a versatile approach to antiviral treatment.

Where can I find the latest news about AIkido Pharma Inc.?

The latest news about AIkido Pharma Inc. can be found on their official website and major financial news platforms.

aiki

Nasdaq:AIKI

AIKI Rankings

AIKI Stock Data

19.53M
Payroll Services
Professional, Scientific, and Technical Services
Link
US
New York